Table 4 Comparison of characteristics between arthritis and OA in pSS patients with arthralgia
Variable | pSS with arthritis | pSS with OA | p value |
|---|---|---|---|
n = 12 | n = 84 | ||
Female (n, %) | 12(100.0) | 78(92.9) | 0.750 |
Age (year), x ± s | 51 ± 14.5 | 62 ± 10.0 | 0.001 |
Disease duration (year) M (IQR) | 5(1.8–7.8) | 5(2–10) | 0.341 |
ESSDAI score M (IQR) | 7(4.8–8.5) | 4(2.0–7.0) | 0.005 |
Clinical manifestation (n, %) | |||
Dry mouth | 12(100.0) | 72(85.7) | 0.351 |
Objective | 7(100.0) | 59(93.7) | 1.000 |
Dry eye | 9(75.0) | 57(67.9) | 0.868 |
Objective | 5(100.0) | 23(95.8) | 1.000 |
Swollen parotid gland | 1(8.3) | 11(13.1) | 1.000 |
Renault phenomenon | 1(8.3) | 10(11.9) | 1.000 |
Lymphadenopathy | 1(8.3) | 3(3.6) | 1.000 |
Cutaneous | 3(25.0) | 2(2.4) | 0.013 |
Pulmonary | 2(16.7) | 15(17.9) | 1.000 |
Renal | 1(8.3) | 2(2.4) | 0.825 |
Muscular | 1(8.3) | 1(1.2) | 0.107 |
Peripheral nervous system | 1(8.3) | 3(3.6) | 1.000 |
Hematological | 6(50.0) | 53(63.1) | 0.579 |
Laboratory data | |||
Hemoglobin (g/L), x ± s | 123 ± 16.5 | 121 ± 12.4 | 0.590 |
A/G | 1.2 ± 0.3 | 1.3 ± 0.3 | 0.428 |
Globulin (g/L), x ± s | 32.6 ± 6.5 | 31.9 ± 6.1 | 0.696 |
UA (umol/L), M (IQR) | 217(163.8–300.5) | 284(230.0–335.0) | 0.042 |
TC (mmol/L), M (IQR) | 4.7(3.9–5.5) | 4.8(4.0–5.4) | 0.934 |
TG (mmol/L), M (IQR) | 0.9(0.8–1.1) | 1.3(0.9–1.7) | 0.040 |
HDL (mmol/L), M (IQR) | 1.1(1.0–1.6) | 1.2(1.0–1.4) | 0.980 |
FBG (mmol/L), x ± s | 4.8 ± 0.5 | 5.0 ± 1.3 | 0.533 |
C3 (g/L), x ± s | 1.0 ± 0.2 | 1.0 ± 0.2 | 0.741 |
C4 (g/L), x ± s | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.166 |
ANA positive (n, %) | 10(83.3) | 50(60.2) | 0.219 |
Anti-SSA (n, %) | 9(75.0) | 50(60.2) | 0.505 |
Anti-SSB (n, %) | 3(25.0) | 22(26.5) | 1.000 |
Anti-CCP (n, %) | 1(9.1) | 3(4.2) | 1.000 |
Increased RF (n, %) | 4(33.3) | 16(22.2) | 0.638 |
IgA (g/L), x ± s | 2.3 ± 0.9 | 3.0 ± 1.5 | 0.170 |
IgM (g/L), x ± s | 1.1 ± 0.5 | 1.5 ± 1.4 | 0.418 |
IgG (g/L), x ± s | 16.1 ± 5.4 | 15.0 ± 4.4 | 0.459 |
IgG4 (g/L), x ± s | 0.5 ± 0.6 | 0.8 ± 3.0 | 0.791 |
Increased CRP (n, %) | 1(8.3) | 6(7.3) | 1.000 |
Increased ESR (n, %) | 2(16.7) | 25(30.9) | 0.503 |
Decreased 25-(OH)D (n, %) | 3(37.5) | 16(21.9) | 0.584 |